Program
elacestrant
Also written as “Elacestrant”, “RAD1901” and “Elacestrant dihydrochloride”.
Its studies are mostly in Breast Neoplasms · Hot Flashes, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Menarini Group | 95 open or running | phase 3since Dec 3, 2018 | Dec 31, 2014 | Nov 2026phase 2 · NCT05596409 |
| Radius Pharmaceuticals | 20 open or running | phase 2since Mar 6, 2009 | Mar 6, 2009 | none ahead |
| Criterium | 10 open or running | phase 2since Dec 30, 2020 | Dec 30, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2009First study: phase 2 study in Hot FlashesNew to Radius PharmaceuticalsRadius Pharmaceuticals · NCT00875420 · 100 enrolled · United States
- Dec 31, 2014Menarini Group's first study: phase 1 study in Advanced ER+, HER2-Negative Breast CancerNew to Menarini GroupMenarini Group · NCT02338349 · 57 enrolled · United States
- Jan 6, 2016Phase 1 study in Breast NeoplasmsMenarini Group · NCT02650817 · 16 enrolled · Belgium, Netherlands
- Jan 8, 2016Phase 2 study in Hot FlashesRadius Pharmaceuticals · NCT02653417 · 139 enrolled · United States
- Dec 3, 2018Phase 3 study in Breast NeoplasmsMenarini Group · NCT03778931 · 478 enrolled · United States, Argentina, Australia and more
- Dec 30, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04791384 · 5 enrolled · United States
- May 16, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05386108 · 73 planned · United States, Belgium, France and more
- Sep 22, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05563220 · 435 enrolled · United States, Argentina, Australia and more
- Oct 24, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05596409 · 61 enrolled · United States, Brazil, Bulgaria and more
- Nov 6, 2023Phase 1 study in Breast NeoplasmsMenarini Group · NCT06126575 · 16 enrolled · United States
- Jul 1, 2024Phase 3 study in Breast NeoplasmsMenarini Group · NCT06492616 · 4,556 enrolled · United States, Argentina, Australia and more
- Aug 10, 2026Phase 2 study in Breast NeoplasmsMenarini Group · NCT07766018 · 70 planned · Japan
Ahead
- Nov 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05596409
- Dec 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05386108
- Dec 27, 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05563220
- Oct 2028Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT07766018
TargetBeta
“An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity”NCIt, by rule
“Estrogen receptor alpha degrader; Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07766018Breast Neoplasms · Japan | 2 | Recruiting | Menarini Group | Oct 2028 | 70 |
| NCT06492616Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Menarini Group | Aug 2029 | 4,556 |
| NCT06126575Breast Neoplasms · United States | 1 | Completed | Menarini Group | Nov 11, 2024 | 16 |
| NCT05596409Breast Neoplasms · United States, Brazil, Bulgaria and more | 2 | Active, not recruiting | Menarini Group | Nov 2026 | 61 |
| NCT05563220Breast Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Menarini Group | Dec 27, 2026 | 435 |
| NCT05386108Breast Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Menarini Group | Dec 2026 | 73 |
| NCT04791384Breast Neoplasms · United States | 2 | Terminated | Criterium | Sep 16, 2024 | 5 |
| NCT03778931Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Menarini Group | Aug 24, 2021 | 478 |
| NCT02653417Hot Flashes · United States | 2 | Terminated | Radius Pharmaceuticals | Dec 12, 2016 | 139 |
| NCT02650817Breast Neoplasms · Belgium, Netherlands | 1 | Completed | Menarini Group | Aug 30, 2018 | 16 |
| NCT02338349Advanced ER+, HER2-Negative Breast Cancer · United States | 1 | Completed | Menarini Group | Sep 2019 | 57 |
| NCT00875420Hot Flashes · United States | 2 | Completed | Radius Pharmaceuticals | Jan 2010 | 100 |
How it is read
Names in the registry
- “Elacestrant”, 8 entries
- “RAD1901”, 6 entries
- “Elacestrant dihydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Hot Flashes, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.